Investors Overview
Cellular Therapy, Regenerative Medicine, and Clinical-Grade Islet Cells
Cellular therapy is a forerunner in the promising field of regenerative medicine.
In an experimental procedure called islet transplantation, islet cells (islets of
Langerhans) are taken
from a donor pancreas and transferred into a person with type 1 diabetes. Once implanted,
the beta cells in these islets begin to produce and release insulin.
Named after these affected insulin-producing beta cells, Beta-Pro LLC, was
formed to facilitate a functional cure for diabetes. We believe cellular therapy
is critical in the fight
against diabetes and have found a way to harvest donor organs that would otherwise be discarded for the benefit of the diabetes research community.
Beta-Pro Partners with IIAM to Obtain Organs from Donors for Diabetes Research
Nearly 25 percent of gathered donor pancreases are suitable for whole organ transplantation.
In order to obtain organs from donors, Beta-Pro partners with the
International Institute for the Advancement of Medicine (IIAM), one of the
largest recovery networks in the world for the acquisition of donated human tissue
for research and education. After successful procurement:
- Beta-Pro works closely with the University of Virginia Center for Cellular Transplantation
and Therapeutics, subsequently capturing this surplus of unwanted organs for islet cell isolation, processing, expansion, and
testing.
-
Beta-Pro then distributes customized islet cells to medical centers and other organizations
for diabetes research.
These
clinical-grade islets are manufactured in a Current Good Manufacturing Practices
(cGMP) “clean room” facility approved by the U.S. Food and Drug Administration.
At present, Beta-Pro is making good use of unwanted organs that would otherwise
be discarded. We are supplying clinical-grade human islets and human stem
cells to numerous organizations for the purposes of research and bettering the lives
of people with diabetes and other autoimmune diseases.
Contact Beta-Pro for More Information on Investment Opportunities
For more information about Beta-Pro biotechnology investment opportunities, please
contact:
Joe Shields
Beta-Pro Director of Public Relations
800.959.2066 ext. 131
|